Business
Trading update & Notice of results
Trading update & Notice of results.
About this update from Tristel Plc
[{"type":"text","content":"\n \nRNS Number : 5194U Tristel PLC 13 July 2018 \n\nTristel plc\n(\"Tristel\" or \"the Company\")\n \nTrading update & Notice of results\n \nTristel plc (AIM: TSTL), the manufacturer of infection prevention products, provides a trading update for the year ended 30 June 2018 in advance of the Shareholder Open Day to be held at its headquarters in Snailwell, Cambridgeshire on Tuesday 17 July. \n \nFor the year ended 30 June 2018 results will be in line with expectations, showing strong growth across the business. Tristel will report record turnover of £22.2m (2017: £20.3m) and pre-tax profit (before share-based payments) of at least £4.4m (2017: £4.1m). Revenue from overseas markets contributed 51.3% of the Group total - a record level (2017: 47%). Tristel has continued to generate significant levels of cash and at 30 June 2018 cash balances were £6.7m (30 June 2017: £5.1m). The Company has no debt.\n \nThe Company will declare a final dividend for the year ended 30 June 2018 at the time of the preliminary results to be announced in October. \n \nNorth America\n \nBuilding upon the EPA approval granted on 19 April, the Company is filing an additional submission to expand the allowable microbiological efficacy claims (20 additional micro-organisms) to enhance the competitive advantage of its Duo product. It is also in the process of filing registrations in the first five selected States, and is adding a second foam-based product format to its registration. This product is branded Jet in the UK and overseas markets and utilises the same chemistry as Duo. Manufacturing scale up is underway at Parker Laboratories.\n \nThe Company has lodged a pre-submission review with the FDA in accordance with the guidance given by the agency in the initial consultation meeting in April 2016. The data set presented to the FDA represents a substantial portion of the final submission that the Company continues to expect to make by the end of the calendar year. The FDA will provide a written response to the pre-submission review 90 days from receipt. This response will be used by the Company to guide its final submission.\n \nMobile ODT (\"MODT\")\n \nMODT is in the process of completing a further US$5m fund raising as it continues the global roll-out of its...